Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study
Inflammatory Bowel Diseases · 01.11.2026 · 32 (11) · 2103-2109
DOI: 10.1093/ibd/izag103 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.06.2026. Verfasst von Nabeel Khan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA 19104, United States. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Inflammatory Bowel Diseases, Hospitalization. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Data describing the incidence and clinical outcomes of respiratory syncytial virus (RSV) infection among patients with inflammatory bowel disease (IBD) are limited.
Methods
We conducted a nationwide retrospective cohort study using the Veterans Health Administration (VHA) database. Adults with IBD were identified using a previously validated algorithm and matched 1:2 to non-IBD controls using propensity score matching. Laboratory-confirmed RSV infections that occurred between January 1, 2021, and December 31, 2024, were identified using standardized laboratory codes and confirmed by manual chart adjudication. Primary outcomes included RSV incidence and hospitalizations. Secondary outcomes included intensive care unit (ICU) admission and patient outcomes stratified by IBD medication class.
Results
After propensity score matching, 52 740 IBD patients and 104 997 non-IBD controls were included. Infection with RSV occurred in 219 patients with IBD and 426 non-IBD patients. Incidence rates of RSV were similar between cohorts across all years in our study period. Hospitalization related to RSV occurred in 18.26% of IBD-RSV patients compared with 13.15% of non-IBD patients (P = .08). ICU admission was rare in both groups (<1%). Among patients with IBD, RSV-related hospitalization did not differ significantly by medication class, when comparing biologic therapy (8.93%) with 5-aminosalicylic acid monotherapy (17.58%) (P = .15).
Conclusions
In this nationwide cohort, patients with IBD, with predominantly lower exposure to advanced therapies, did not have higher rates of RSV infection or worse clinical outcomes compared with matched non-IBD controls. RSV outcomes were similar across IBD medication classes. These findings support current vaccination recommendations and provide reassurance regarding RSV risk among patients with IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA 19104, United States.
- Division of Gastroenterology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, United States.
- Division of Gastroenterology and Hepatology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI 53705, United States.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL 32224, United States.
ORCID-Profile: Nabeel Khan, Ramaswamy Sundararajan, Freddy Caldera
Zitieren
APA
Khan, N., Sundararajan, R., Caldera, F., & Farraye, F. A. (2026). Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study. Inflammatory Bowel Diseases, 32(11), 2103-2109. https://doi.org/10.1093/ibd/izag103
Vancouver
Khan N, Sundararajan R, Caldera F, Farraye FA. Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study. Inflammatory Bowel Diseases. 2026;32(11):2103-2109. doi:10.1093/ibd/izag103
BibTeX
@article{Khan2026,
author = {Khan, Nabeel and Sundararajan, Ramaswamy and Caldera, Freddy and Farraye, Francis A},
title = {Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {11},
pages = {2103--2109},
doi = {10.1093/ibd/izag103}
}
EUVIMED